These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29272749)

  • 1. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
    Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
    Eur J Med Chem; 2018 Jan; 144():179-200. PubMed ID: 29272749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors.
    Righetti G; Casale M; Liessi N; Tasso B; Salis A; Tonelli M; Millo E; Pedemonte N; Fossa P; Cichero E
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
    Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
    Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
    Vaccarin C; Veit G; Hegedus T; Torres O; Chilin A; Lukacs GL; Marzaro G
    J Med Chem; 2024 Aug; 67(16):13891-13908. PubMed ID: 39137389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.
    Nieddu E; Pollarolo B; Mazzei MT; Anzaldi M; Schenone S; Pedemonte N; Galietta LJ; Mazzei M
    Arch Pharm (Weinheim); 2016 Feb; 349(2):112-23. PubMed ID: 26701662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
    Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
    Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
    Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
    Laselva O; Molinski S; Casavola V; Bear CE
    Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
    Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
    Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
    J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.